NYSE:BIO
Bio-rad Laboratories, Inc.
Bio-rad Laboratories, Inc.'s revenue grew 0.7% in fiscal 2025 to $2.6B while operating margin fell to 1.8%. Free cash flow was $374.6M, 14.5% of revenue, and the diluted share count fell 3.3%.Summary generated from Bio-rad Laboratories, Inc.'s SEC filings. Latest annual report filed Feb 13, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.6B
Revenue growth+0.7%
Revenue, 5-yr CAGR+0.3%
Gross margin51.9%
Operating margin1.8%
Net margin29.4%
ROIC0.5%
Return on equity10.8%
Debt / equity0.16
Free cash flow$374.6M
FCF margin14.5%
Share count change−3.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2,923 | 2,802 | 2,671 | 2,567 | 2,583 |
| Operating income | 500 | 483 | 338 | 269 | 47 |
| Net income | 4,254 | −3,628 | −637 | −1,844 | 760 |
| Free cash flow | 536 | 82 | 218 | 290 | 375 |
Recent filings
- 4Insider transaction report
Sep 9, 2026 - 4Insider transaction report
Sep 9, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 30, 2026 - 8-KResults of operations and financial condition
Apr 30, 2026 - 8-KDirector or officer change
Apr 24, 2026 - DEF 14AProxy statement
Mar 25, 2026